Destination XL and FullBeauty agree to merge into a $1.2 billion plus-size retailer
Two plus-size clothing specialists are merging into a roughly $1.2 billion company, which could leave shoppers with fewer independent places to find extended sizes.
Destination XL Group and FullBeauty Brands have agreed to combine in an all-stock merger of equals, creating an inclusive-apparel retailer that the two companies value at roughly $1.2 billion [1]. The deal was announced on December 11, 2025 [1].
Destination XL is a big-and-tall men's apparel retailer, and FullBeauty is a plus-size women's retailer [1]. In announcing the combination, the companies described it as creating a "scaled, category-defining retailer for inclusive apparel" [1]. That phrase points to the stated rationale: scale. Two midsize specialists in extended sizes are joining into one larger company rather than continuing to compete for the same customers [1].
The transaction is all-stock and is structured as a merger of equals, meaning neither company is buying the other with cash [1]. In a deal like that, shareholders of both companies would end up owning part of the combined business, with the split set by an exchange ratio. The announcement did not include that ratio, and it also left out other details that usually accompany a deal of this size: who will run the combined business, which brand names will survive, how many stores it will operate, and when the deal is expected to close [1].
The announcement does not mention GLP-1 medications, including semaglutide (sold as Ozempic, Wegovy and Rybelsus) or tirzepatide (sold as Mounjaro and Zepbound), and it does not say whether weight-loss drug prescribing played any role in the decision [1]. No figures on how GLP-1 use may be changing demand for extended sizes were included [1]. Whether the two companies see the combination as a response to changing demand or simply as a way to gain buying power and cut costs has not been reported [1].
Why it matters for patients
For shoppers who buy extended sizes, the effects would show up in ordinary places: which stores stay open, which websites and loyalty programs merge, which brands stay on the rack, and how returns work. When two of the largest remaining specialists in a category combine, there are fewer independent places to buy those sizes, and selection and pricing are set by one company instead of two [1]. The companies have not said what will change for customers, or when [1].
The announcement covers clothing retail only. It does not change how GLP-1 medications are prescribed, covered by insurance, or priced [1]. People who lose weight while taking semaglutide or tirzepatide often need different clothing sizes, and how a smaller group of large retailers responds to that shift in demand is not yet known [1].
What happens next
No closing date has been announced [1]. The steps that would typically follow a merger announcement of this kind, such as shareholder votes and any antitrust review, have not been disclosed, and neither company has said when the combined business would begin operating under a single structure [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.